Contemporary management of chronic obstructive pulmonary disease: scientific review

Author(s): Sin DD, McAlister FA, Man SF, Anthonisen NR


Context: The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course.

Objective: To systematically review the impact of long-acting bronchodilators, inhaled corticosteroids, nocturnal noninvasive mechanical ventilation, pulmonary rehabilitation, domiciliary oxygen therapy, and disease management programs on clinical outcomes in patients with COPD.

Data sources: MEDLINE and Cochrane databases were searched to identify all randomized controlled trials and systematic reviews from 1980 to May 2002 evaluating interventions in patients with COPD. We also hand searched bibliographies of relevant articles and contacted experts in the field.

Study selection and data extraction: We included randomized controlled trials that had follow-up of at least 3 months and contained data on at least 1 of these clinical outcomes: health-related quality of life, exacerbations associated with COPD, or death. For pulmonary rehabilitation, we included studies that had a follow-up of at least 6 weeks. Using standard meta-analytic techniques, the effects of interventions were compared with placebo or with usual care. In secondary analyses, the effects of interventions were compared against each other, where possible.

Data synthesis: Long-acting beta2-agonists and anticholinergics (tiotropium) reduced exacerbation rates by approximately 20% to 25% (relative risk [RR] for long-acting beta2-agonists, 0.79; 95% CI, 0.69-0.90; RR for tiotropium, 0.74; 95% CI, 0.62-0.89) in patients with moderate to severe COPD. Inhaled corticosteroids also reduced exacerbation rates by a similar amount (RR, 0.76; 95% CI, 0.72-0.80). The beneficial effects were most pronounced in trials enrolling patients with FEV1 between 1 L and 2 L. Combining a long-acting beta2-agonist with an inhaled corticosteroid resulted in an approximate 30% (RR, 0.70; 95% CI, 0.62-0.78) reduction in exacerbations. Pulmonary rehabilitation improved the health status of patients with moderate to severe disease, but no material effect was observed on long-term survival or hospitalization rates. Domiciliary oxygen therapy improved survival by approximately 40% in patients with PaO2 lower than 60 mm Hg, but not in those without hypoxia at rest. The data on disease management programs were heterogeneous, but overall no effect was observed on survival or risk of hospitalization. Noninvasive mechanical ventilation was not associated with improved outcomes.

Conclusions: A significant body of evidence supports the use of long-acting bronchodilators and inhaled corticosteroids in reducing exacerbations in patients with moderate to severe COPD. Domiciliary oxygen therapy is the only intervention that has been demonstrated to prolong survival, but only in patients with resting hypoxia.

Similar Articles

Chronic obstructive pulmonary disease surveillance - United States, 1971-2000

Author(s): Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC

Bronchodilators in chronic air-flow limitation

Author(s): Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, et al.

Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD

Author(s): Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, et al.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Author(s): Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al.

Oral theophylline for chronic obstructive pulmonary disease

Author(s): Ram FS, Jones PW, Castro AA, DeBerito JA, Atallah AN, et al.

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

Author(s): Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al.

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

Author(s): Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, et al.

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study

Author(s): Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, et al.

Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial

Author(s): Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, et al.

Corticosteroids contribute to muscle weakness in chronic airflow obstruction

Author(s): Decramer M, Lacquet LM, Fagard R, Rogiers P

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

Author(s): Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, et al.

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

Author(s): Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, et al.

Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients

Author(s): Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

Author(s): Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, et al.

Marked sympathetic activation in patients with chronic respiratory failure

Author(s): Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S

Appropriateness of domiciliary oxygen delivery

Author(s): Guyatt GH, McKim DA, Austin P, Bryan R, Norgren J, et al.

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial

Author(s): Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, et al.

Controlled trial of oral prednisone in outpatients with acute COPD exacerbation

Author(s): Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease

Author(s): Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, et al.

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

Author(s): Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, et al.

Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis

Author(s): Jorgensen AF, Coolidge J, Pedersen PA, Peterson KP, Waldorff S, et al.